AbbVie press release
NORTH CHICAGO, Ill., June 23, 2026 — AbbVie (NYSE: ABBV) today announced that the European Commission approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged 3 years and older. With this approval, MAVIRET is now the only treatment approved in the European Union for both acute and chronic HCV infection.
The approval was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of MAVIRET eight-week treatment regimen in patients with acute HCV infection. The study results showed MAVIRET to be a highly efficacious treatment for people with acute HCV. The majority of the adverse events reported were mild or moderate in severity. The most common adverse events were fatigue, diarrhea, headache, and asthenia.
AbbVie continues to collaborate with global regulatory authorities to support access to MAVIRET for people living with acute HCV infection. MAVIRET is approved in the United States, Saudi Arabia, New Zealand, Canada, Taiwan, Australia and Argentina for the treatment of acute and chronic HCV infection in adults and children aged 3 years and older.
Read the full press release here.
Source : AbbVie
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.